Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.

Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y.

Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12210-5. doi: 10.1073/pnas.1007186107. Epub 2010 Jun 21.

2.

Is miR-29 an oncogene or tumor suppressor in CLL?

Pekarsky Y, Croce CM.

Oncotarget. 2010 Jul;1(3):224-7.

3.

CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.

Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM, Pekarsky Y.

Leukemia. 2010 May;24(5):970-5. doi: 10.1038/leu.2010.46. Epub 2010 Apr 1.

4.

MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ.

Blood. 2014 Jul 24;124(4):546-54. doi: 10.1182/blood-2014-03-559690. Epub 2014 Jun 9.

5.

Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.

Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60.

6.

Molecular basis of CLL.

Pekarsky Y, Zanesi N, Croce CM.

Semin Cancer Biol. 2010 Dec;20(6):370-6. doi: 10.1016/j.semcancer.2010.09.003. Epub 2010 Sep 21. Review.

7.

miR-15b/16-2 deletion promotes B-cell malignancies.

Lovat F, Fassan M, Gasparini P, Rizzotto L, Cascione L, Pizzi M, Vicentini C, Balatti V, Palmieri D, Costinean S, Croce CM.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11636-41. doi: 10.1073/pnas.1514954112. Epub 2015 Aug 31.

8.

Novel insights in molecular mechanisms of CLL.

Zanesi N, Balatti V, Bottoni A, Croce CM, Pekarsky Y.

Curr Pharm Des. 2012;18(23):3363-72. Review.

PMID:
22591386
9.

miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression.

Wang M, Tan LP, Dijkstra MK, van Lom K, Robertus JL, Harms G, Blokzijl T, Kooistra K, van T'veer MB, Rosati S, Visser L, Jongen-Lavrencic M, Kluin PM, van den Berg A.

J Pathol. 2008 May;215(1):13-20. doi: 10.1002/path.2333.

PMID:
18348159
10.

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM.

Cancer Res. 2006 Dec 15;66(24):11590-3.

11.

B-cell malignancies in microRNA Eμ-miR-17~92 transgenic mice.

Sandhu SK, Fassan M, Volinia S, Lovat F, Balatti V, Pekarsky Y, Croce CM.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18208-13. doi: 10.1073/pnas.1315365110. Epub 2013 Oct 21.

12.

The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.

Bomben R, Gobessi S, Dal Bo M, Volinia S, Marconi D, Tissino E, Benedetti D, Zucchetto A, Rossi D, Gaidano G, Del Poeta G, Laurenti L, Efremov DG, Gattei V.

Leukemia. 2012 Jul;26(7):1584-93. doi: 10.1038/leu.2012.44. Epub 2012 Feb 20.

PMID:
22343732
13.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Aug 14;6(23):19807-18.

14.

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, Dalla-Favera R.

Cancer Cell. 2010 Jan 19;17(1):28-40. doi: 10.1016/j.ccr.2009.11.019. Epub 2010 Jan 7.

15.

MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.

Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD.

PLoS One. 2011 Mar 8;6(3):e16956. doi: 10.1371/journal.pone.0016956.

16.
17.

Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL).

Kasar S, Underbayev C, Hassan M, Ilev I, Degheidy H, Bauer S, Marti G, Lutz C, Raveche E, Batish M.

PLoS One. 2016 Mar 9;11(3):e0149331. doi: 10.1371/journal.pone.0149331. eCollection 2016.

18.

Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5(+) B cell expansion.

Palmer VL, Nganga VK, Rothermund ME, Perry GA, Swanson PC.

BMC Immunol. 2015 Nov 4;16:66. doi: 10.1186/s12865-015-0130-z.

19.

Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.

Romano C, Sellitto A, Chiurazzi F, Simeone L, De Fanis U, Raia M, Del Vecchio L, Lucivero G.

Int J Hematol. 2015 Jan;101(1):67-74. doi: 10.1007/s12185-014-1703-y. Epub 2014 Nov 29.

PMID:
25432435
20.

H-2z homozygous New Zealand mice as a model for B-cell chronic lymphocytic leukemia: elevated bcl-2 expression in CD5 B cells at premalignant and malignant stages.

Okamoto H, Nishimura H, Shinozaki A, Zhang D, Hirose S, Shirai T.

Jpn J Cancer Res. 1993 Dec;84(12):1273-8.

PMID:
7507474

Supplemental Content

Support Center